Valvular & structural heart diseaseSecondary analysis
Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY Transcatheter Aortic Valve Replacement (TAVR) Trial
- Secondary analysis of the EARLY TAVR randomised trial
- subgroup analysis by baseline biomarker levels
- core laboratory
Authors' conclusion
In patients with asymptomatic severe high-gradient aortic stenosis, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates, as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in patients with the lowest biomarker levels.
Study context
- Population
- Patients with asymptomatic severe aortic stenosis798 (89%) with biospecimens
- Participants
- 901 patients
- Comparison
- Early TAVR vs Clinical surveillance
- Primary endpoint
- Trial primary end point (death, stroke or unplanned CV hospitalization) by baseline biomarker level; interaction with treatment
Primary result
As reported in the abstract
High-sensitivity cardiac troponin T (hs-cTnT) × treatment interaction for death or HF hospitalization: greater relative benefit with normal hs-cTnT
P interaction=0.04
hs-cTnT × treatment interaction for HF hospitalization alone
P interaction=0.03
Secondary outcomes
Baseline biomarker levels
- Median NT-proBNP
- 287 [145, 601]
- Median hs-cTnT
- 14.6 [10.5, 21.0]
Original publication
Summarised from the published abstract; every number is checked against it